<DOC>
	<DOCNO>NCT00404261</DOCNO>
	<brief_summary>The purpose study evaluate level satisfaction experience asthma chronic obstructive pulmonary disease ( COPD ) patient use Fluticasone/Salmeterol HFA Metered Dose Inhaler ( MDI ) counter , compare use Fluticasone/Salmeterol HFA MDI without counter .</brief_summary>
	<brief_title>Evaluation Of Patient Satisfaction Of Metered Dose Inhaler ( MDI ) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients ( COPD ) .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Outpatient Documented physician diagnosis asthma COPD Requires use controller long act beta 2 agonist Ability provide write informed consent Patients life threaten asthma COPD Historical current evidence significant disease Immediate delay hypersensitivity inhale short act beta2agonist sympathomimetic drug component MDI formulation History drug alcohol abuse Abnormal chest x ray consistent asthma COPD Use supplemental oxygen ; systemic corticosteroid ; short act beta2agonists VENTOLIN HFA ; antibiotic respiratory infection ; antiarrhythmic ; anticonvulsant ; central nervous system stimulant ; tricyclic antidepressant monoamine oxidase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Fluticasone Propionate</keyword>
	<keyword>healthcare professional satisfaction</keyword>
	<keyword>patient satisfaction</keyword>
	<keyword>meter dose inhaler counter</keyword>
	<keyword>Salmeterol</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
</DOC>